{"id":3810,"date":"2026-10-21T09:00:00","date_gmt":"2026-10-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3810"},"modified":"2026-10-21T20:36:19","modified_gmt":"2026-10-22T00:36:19","slug":"us-cooperative-group-will-test-ivonescimab-in-biliary-cancer","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3810","title":{"rendered":"US Cooperative Group Will Test Ivonescimab in Biliary Cancer"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Akeso; Summit Therapeutics; ECOG-ACRIN<\/p>\n

Event Type<\/strong><\/p>\n

Development Collaboration (registration-enabling Phase 2\/3 trial)<\/p>\n

Modality<\/strong><\/p>\n

PD-1\/VEGF bispecific antibody<\/p>\n

Asset<\/strong><\/p>\n

Ivonescimab (EA2251)<\/p>\n

Target<\/strong><\/p>\n

PD-1; VEGF<\/p>\n

Disease Area<\/strong><\/p>\n

First-line advanced biliary tract cancer<\/p>\n

Summary<\/h4>\n

Summit and the US ECOG-ACRIN research group announced a registration-enabling phase 2\/3 study of Akeso-originated ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The notable signal is a prospective test of whether a China-derived survival finding translates to a US population and a contemporary active comparator.<\/p>\n

EA2251 (NCT07765433) will randomize US patients to ivonescimab plus gemcitabine-cisplatin or pembrolizumab\/durvalumab plus the same chemotherapy. Overall survival is the primary endpoint; sites are expected to activate in fourth-quarter 2026. Akeso reported an overall-survival benefit versus durvalumab plus chemotherapy in the China HARMONi-GI1 trial in August, but detailed results are scheduled for 25 October and were not disclosed today. Summit will supply drug and funding; financial collaboration terms were not provided.<\/p>\n

Deep Analysis<\/h4>\n

The trial design addresses regulatory portability directly: it tests the bispecific against approved checkpoint-plus-chemotherapy standards in the region where Summit holds rights. A cooperative group network may improve accrual in a relatively uncommon cancer. The agent combines PD-1 blockade with VEGF binding, but whether dual targeting improves survival over the current regimen is unproven outside the China study.<\/p>\n

The competing interpretation is that the China signal may depend on population mix, disease subtype, prior care, comparator execution or regional treatment practice. Without full HARMONi-GI1 hazard ratios, safety and subgroup data, magnitude cannot be independently judged. No upfront or milestone economics are newly disclosed; this is a development collaboration, not a new licensing value event.<\/p>\n

Company and Product Background<\/h4>\n

Ivonescimab is an Akeso-developed PD-1\/VEGF bispecific antibody licensed to Summit in the US and several other regions. Advanced biliary tract cancers include cholangiocarcinoma and gallbladder cancer; gemcitabine-cisplatin plus PD-1 or PD-L1 blockade is a current first-line standard.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Fact:<\/strong> a US randomized phase 2\/3 protocol and active comparator have been announced.<\/li>\n
  • Company claim:<\/strong> prior China phase 3 interim analysis favored ivonescimab; full data are pending.<\/li>\n
  • Upgrade:<\/strong> reproducible US overall-survival benefit with acceptable bleeding and vascular toxicity. Falsifier:<\/strong> failure versus checkpoint-based standard care.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: EA2251 is a well-aimed cross-border validation step. It should not be treated as confirmation that the reported China efficacy will generalize.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: Neutral. Confidence in Facts: High. Confidence in Interpretation: Moderate. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Summit and the US ECOG-ACRIN research group announced a registration-enabling phase 2\/3 study of Akeso-originated ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The notable signal is a prospective test of whether a…<\/p>\n","protected":false},"author":1,"featured_media":3828,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[170,120,1130,521,169],"class_list":["post-3810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-akeso","tag-biliary-tract-cancer","tag-ecog-acrin","tag-ivonescimab","tag-summit-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3810"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3810\/revisions"}],"predecessor-version":[{"id":3829,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3810\/revisions\/3829"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3828"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}